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Available online 12 March 2018Electric ﬁeld-induced membrane changes are an important approach in the life sciences. However, the develop-
ments in knowledge and translational applications face problems of reproducibility. Indeed, a quick survey of the
literature reveals a lack of transparent and comprehensive reporting of essential technical information in many
papers. Too many of the published scientiﬁc papers do not contain sufﬁcient information for proper assessment
of the presented results. The general rule/guidance in reporting experimental data should require details on ex-
posure conditions such that other researchers are able to evaluate, judge and reproduce the experiments and data
obtained. To enhance dissemination of information and reproducibility of protocols, it is important to agree upon
nomenclature and reach a consensus on documentation of experimental methods and procedures. This paper of-
fers recommendations and requirements for reporting on applications of electric pulse delivery for electropora-
tion of biological samples in life science.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Electroporation1. Introduction
This manuscript outlines a proposal for deﬁned nomenclature and
guidance for reporting of materials and methods related to the use of
electroporation of biological samples in the life sciences, for both
in vitro and in vivo applications. This paper is presented in support of
the Electroporation-Based Technologies and Treatments courses
(EBTT) (http://2017.ebtt.org/) that supply participants with sufﬁcient
theoretical background and practical knowledge for effective use of
electroporation in their working environments. This work is intended
as a complete set of advice and suggestions on the information that
should be included in scientiﬁc papers to fully describe the results.
As a general rule/guidance in reporting, experimental data should con-
tain details on exposure conditions such that that other researchers are
able to evaluate, judge and reproduce the experiments and data obtained.
This type of reporting is necessary for future systematic reviews and/or
meta-analyses, which are studies that systematically assess previous re-
search andderive conclusions that cannot be extracted fromsingle studies
[1–4]. The outcomes of meta-analyses can lead to further advances in the
ﬁeld of electroporation-based technologies [2,5]. Offering adequate de-
scription ofmaterials andmethods used in the studypresents an apparent
contradiction with the trend towards papers that are more concise and. This is an open access article undershorter in length, but many journals now offer publication of additional
(Supplemental) material online. We should all embrace these options.
Such a conclusion on the need for recommendation and guidance on
reporting materials and methods is shared by many practitioners [6–8].
Common agreement exists that recommendations are needed to improve
the consistency and quality of reporting in life science articles [9–11]. The
Global Biological Standards Institute (GBSI) presented a report making a
case for biological standards in the life sciences. In interviews in the life
science community, working with irreproducible data and/or results
was emphasized as a serious issue. The conclusion of the GBSI was that
“there is a need for more well-deﬁned and consistently used standards,
both material (reference reagents and chemicals) and written (optimal
practices andmethodologies). This need is urgent because life science re-
search is increasing in its complexity. Due to economic pressure, conclu-
sions must be rapidly available for translational opportunities, mostly
for medical applications. To facilitate interpretation and improve the reli-
ability of published results in life and health sciences, we need to report
key protocol details more systematically, examine the statistics more
closely and offer additional ways for authors to be transparent about
thesematters. If researchers detailed their exploratory studiesmore accu-
rately, late-stage trials would be better planned and executed” [12].
The current recommendation guidelines target all electroporation-
based applications of delivery of electric pulses to cells and tissues (in
which most work is performed with batch processes and electrodes are
held at a ﬁxed position during pulse delivery). This scope includesthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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also a result of the discussionswithin the COST TD 1104 action “European
Network for Development of Electroporation Based Technologies and
Treatments”, starting with comments from the steering committee in
Salerno in 2012,wheremembers noticed that inmany presentations, par-
ticipants did not supply sufﬁcient information for other researchers to
properly assess the results. A workshop was subsequently organized
in Copenhagen (2014) to discuss issues related to terminology
and reproducibility issues (http://www.electroporation.net/
Events/COST-TD1104-Management-Committee-Meeting-and-WG-
Meeting-Symposium-March-27-28th). Presenters and discussants
identiﬁed major problems related to reporting of electric pulse delivery
for electroporation of biological samples. Finally, during the 1st World
Congress on Electroporation held in Portoroz, Slovenia during September
6–10, 2015 the decision was made to prepare recommendation papers
speciﬁc to electrochemotherapy [13], food processing [14], and life sci-
ences. Selected critical issues were raised in discussions during the COST
TD 1104 action [15] that should be further highlighted
a- Emphasis on good practice in experimental design
b- Modeling basedondata obtainedon selected reference cells and tissues
c- Uniﬁcation of terminology or a need to supply clear-cut descriptions of
the wording.
In this paper, the above principles for reporting are presented using
examples and critical details discussed in several Appendixes. We have
conceptualized this recommendation paper to make it as short and
comprehensive as possible. Therefore, more extensive descriptions are
added in an appendix. Furthermore, a one-page summary has been pre-
pared and is included at the endof this paper. This summary can be used
as a checklist for authors whenwritingmanuscripts. This work is in line
with CONSORT (Consolidated Standards of Reporting Trials) that offers
“a standard way for authors to describe how trials are designed, ana-
lyzed and interpreted” [12].2. Terminology
The deﬁnition of terms and their explanations are oftenmissing, and
therefore, persistent confusion and misuse of terminology is rife in the
literature. The consequence is poor reproducibility of results, which is
a critical problem for the description of the biological effects of pulsed
electric ﬁelds, a scientiﬁc discipline that is bothmultidisciplinary and in-
terdisciplinary. Different terminologies are found in physical chemistry
and in life science that allow confusion in the reports.
Pulsed electric ﬁeld treatment (PEF treatment, electropulsation, elec-
troporation) is the process of exposing cells in suspensionor tissue to elec-
tric pulses. Electric ﬁeld exposure can be applied via direct, capacitive or
inductive coupling [16–18]. This paper focuses predominantly on research
that applies direct coupling (direct conductive contact of the electrodes
with the sample).With respect to cell suspensions and plant tissue in sus-
pension, this process can be applied either in batch or in continuousmode
[19–21]. The major consequence of PEF treatment is permeabilization of
the plasmamembrane (enhanced transmembrane transport). Oneunder-
lying hypothesis of the basic effects of membrane permeabilization is
formation of defects (known as “pores”, hence electroporation) [22].
An accurate deﬁnition is required because increasingly more new
expressions are used (EP (electropulsation, electropermeabilization, elec-
troporation), ECT (electrochemotherapy), PEF (pulsed electric ﬁeld),
electrogene therapy, GET (gene electrotransfer), electroextraction,
electrofusion, electrochemoembolization). As an example, we use
electrochemotherapy because this term is already widespread. As an
analogy, one could use chemotherapy locally potentiated by electric
pulses. We recommend using gene electrotransfer (GET) rather than
electrogene transfer/therapy (EGT), although the latter is currently
more frequently used.Increased membrane permeability should refer to a given X mole-
cule, which may be small or large. In most experiments, it is the trans-
port of the given X molecule that is assayed, which is different from
increased membrane conductivity, i.e., increased current and increased
suspension conductivity due to increases in ionic leakage and heating
[23,24], but it remains an associated phenomenon, where transport of
X is the key parameter in the assay [22,25].
3. Physical parameters
It is important to standardize the reporting information related to
what is currently referred to as a PEF session, such as a train of pulses
or pulsing frequency vs. pulse repetition frequency. When these terms
are used, it is unclear as to the intended meaning.
Certain PEF parameters are under direct control of the settings of the
electric pulse generator and the deﬁnition of the applicators (elec-
trodes). A key deﬁnition is that one should report the voltage actually
applied between/delivered to the electrodes. The electric ﬁeld is a
more complex parameter that depends on the geometry of the experi-
mental system and on the heterogeneity of the sample (tissue or cell
density) in terms of conductivity and permittivity [26–29]. Furthermore,
whether single or multiple pulses were delivered should be clearly re-
ported. Electropermeabilization is a dynamic process in which local
time-dependent changes in the tissue conductivity occur [30]. This pro-
cess results in a redistribution of the ﬁeld during the pulse application
[31,32].
3.1. Electric pulse generators
The technology that supports pulse generators is complex [33,34].
The type of generator should be described with the speciﬁcation of
whether it is a commercial model or an in-house/built set-up. Because
few pulse generators report/offer reliable and accurate measurement
of U (voltage) and I (current) [35], monitoring of the pulses with digi-
tized recording (and display of the graph) is an important step in ensur-
ing that pulse delivery was obtained as requested from the settings of
the generator. The electrical properties of the sample between the elec-
trodes might affect the current delivered (conductivity change). The
electric charge stored in the generator might fall short of that needed
and affects the proﬁle of the voltage (in the case of long pulses,
i.e., tens of ms, high frequency). It is recommended that treatment pa-
rameters and experimental proﬁles, e.g., voltage and current wave-
forms, are stored for later re-evaluation. A precise description of this
step is required [36]. Authors should report how the voltage (and cur-
rent) was measured, i.e., where and with which instrument(s), and a
schematic drawing of the measurement circuit/setup is helpful.
3.2. Electrodes
Because the electric ﬁeld at a point E(x, y, z) is equal to the negative
gradient of the electric potential, it is strongly dependent on the geometry
of the electrodes to which the voltage is applied [37]. Thus, the geometry
of electrodes and the sample/tissue treated should be described. The de-
sign of the electrodes (cuvette, plate, needles, wires, etc.), including the
composition (material) of the electrodes, should be stated because elec-
trochemical reactions occur during application of the electric pulses that
could affect the sample and consequently the results [38,39].
However, if the equipment is a manufactured product, the authors
should list the reference if the requested info is provided freely on the
web. However, the details on the placement and penetration of needle
electrodes should also be supplied to enable reproduction of the exper-
iment (Appendix 1) and/or to evaluate the electric ﬁeld distribution via
numerical modeling [40] for comparison with other studies.
For use of arrays (using hexagonal electrodes or other types ofmulti-
array electrodes), a complete description of the complex geometry
should be included together with the sequence of pulses delivered
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signiﬁcant inﬂuence on the outcome of treatment [42–44]. This point is
highly important in the case of non-penetrating electrodes or in applica-
tions in which the limited depth of penetration to the skin presents a
major advantage by focusing on the effects on the epidermis [45–47].3.3. Pulse duration
A clear deﬁnition of the temporal pulse parameters is required, such as
the duration of square wave pulses or the decay time constant for expo-
nentially decaying pulses generated by capacitor discharge systems [17].
The decay time constant characterizes the time elapsed until the
pulse voltage value decays to 1/e = 0.3678 of the pulse maximum
(Annex 2). Determination of the decay time constant is only applicable
for resistive and capacitive discharge circuits. For bell-shaped voltage
waveforms (caused in most instances by a non-negligible inﬂuence of
the inductance of a discharge circuit), the pulse should be speciﬁed by
stating either the amplitude, rise-time and fall time of the pulse or the
half width and pulse amplitude (Appendix 2).
The shape of the pulse should be described because it is known to af-
fect the extent ofmembrane permeabilization (exponential decay, square
wave or pseudo-square wave) [48]. Selected information on the voltage
pulse rise-time should be includedwhenever possible because it controls
the charging time of the induced transmembrane voltage (Appendix 2,
Appendix 3). Information on the pulse polarities in a train should be sup-
plied because they are known to control the biological response [49].
Furthermore, the rise-time of a measurement system TrMsys is given
as Tr of the step response of the system (response to an inﬁnite fast-
rising pulse). The bandwidth B and rise-time of themeasurement system
TrMsys are related via the bandwidth-rise-time analogy: B TrMsys = 0.35
(Gaussian systems). The real rise-time of a pulse TrReal is the vector sub-
traction of the rise-time of the measurement system TrMsys from the
rise-time TrDisplay determined at the screen of the oscilloscope: TrReal =
Sqrt(T2rDisplay− T2rMsys) (Fig. 1).
For experiments with nanosecond pulses, it is recommended to spec-
ify themeasurement system used and to also list either the bandwidth or
rise-time of the system. This information becomes important because
pulse duration can be shorter than or of the same order as themembrane
charging time constant. The authors should also mention either the mea-
sured rise-time (as commonly observed in publications if “rise-time” is
mentioned) or the real pulse rise-time according to above considerations
[2]. The rise-time of a pulse ismost often deﬁned as the time between10%
and 90% of the pulse amplitude [17]. Traces of the voltage (and current)
should be presented or given as supplementarymaterial whenever possi-
ble because it has been demonstrated that pulse shape might have a sig-
niﬁcant effect on the observed outcome (e.g., cancelation effect) [49,50].Fig. 1. Inﬂuenceof themeasurement systemproperties ondeterminationof thepulse rise-time.An i
rise-time (B). Thus, thismeasurement system also displays larger values of rise-time (D)whenmea
step response (A). The rise-timeTrDisplay observed at the screenof the oscilloscope (D) is the convoluWhen a train of pulses is delivered, the number of repetitive pulses
and the pulse repetition frequency (or delay between pulses) should
be reported [51]. Memory effects by the cell are present as the ﬁeld ef-
fect is applied on a different membrane organization when resealing is
not fully completed [52]. This effect is known to play a direct role in
the electropermeabilization process and to simultaneously support a
trivial (but damaging) role by increasing the Joule heating [53].
Complex trains, i.e., combinations of different pulses, are currently
popular for gene electrotransfer in preclinical applications such as in
the use of bipolar pulses, which are a combination of high voltage and
low voltage pulses [54–57]. In these applications, the sequence should
be reported with all delays and other parameters (Fig. 2).
Many studies that use commercial devices do not supply the param-
eters of pulses due to a lack of data from the manufacturer [35,58]. In-
stead, the authors list the “program” or “sequence” that they have
selected on the device,which should be documented elsewhere and ref-
erenced in the manuscript, although this practice should be avoided.
Whenever possible, actual physical parameters/pulse parameters and
electrodes should be described. If this information is not available, the
program and catalog number of the device, electrodes, reagents, buffer
and program/sequence used should be listed.
4. Statistical analysis
Raw data or average/mean median as a measure of central tendency
should be listed depending on the data distribution (normal or otherwise)
aswell as ameasureof data spread such as standarddeviation, percentiles,
etc. The number of cells, sample volume, and repetitions of the experi-
ment should also be documented. When normalizing data, i.e., reporting
results in %, care should be taken to avoid reporting percent of a percent.
It should be absolutely clear as towhat reference the resultswere normal-
ized against (Appendix 4). Information on the software package used in
statistical calculations and graphical representation should also be listed.
5. Biochemical and biological parameters
Most journals offer complete instructions for authors, and these
should be carefully followed (for example: https://www.elsevier.com/
journals/bioelectrochemistry/1567-5394/guide-for-authors).
5.1. Chemicals
Manufacturer references are necessary (purity and origin are decisive
parameters in many cases). The sizes of the molecules, the vehicle in
which the chemicals are dissolved, the concentrations used, whether the
solutions were freshly prepared for each experiment and the incubation
times before and after the electroporation procedure should all be stated.nﬁnite fast pulse (A) is displayedby ameasurement systemof limitedbandwidthwitha longer
suring real pulses (C). The rise-time of themeasurement system TrMsys (B) is given as Tr of the
tion of TrMsyswith the real rise-timeof a pulse TrReal (C) that is actually delivered on the sample.
Fig. 2. Example of how to report a complex sequence of pulses. 3 short high voltage pulses are followed by 3 longer low voltage pulses. t1 and t2 – pulse duration; d1 and d2 – interval
(delay) between the pulses; V1 and V2 – amplitude of pulses; l - time lag between pulses of different amplitude. The number of every type of pulse should also be stated. As an
example of complex pulse sequences, see [59].
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dition to pH, authors should report the osmolarity and conductivity (in S/
m), including how and with what (instrument, protocol) these parame-
ters were measured because these factors are known to affect the extent
of permeabilization, the response of cells and the contributing effects due
to Joule heating. After exposure of cells to electric pulses, post-treatment
conditions should also be stated. These conditions include the incubation
time, temperature (of the electroporation buffer or medium as well), and
addition of fetal bovine serum or other additives (e.g., polymers) that af-
fect cell behavior (viability, survival) as a result of the exposure to pulsed
electric ﬁelds.
One problem is the use of patented products from companies for
which such information is not available, except in the patent protecting
the product. In such cases, reference to the patent should be supplied.
5.2. Cells
A complete description of cell systems, as listed below, is required be-
cause this information appears to be a decisive parameter in the biophys-
ical response of the cells exposed to electric pulses. The full name of the
cells, name of the supplier, catalog number when relevant, conﬁrmation
of authentication of the cell line and a statement on mycoplasma testing
should also be included. Such reporting on cell lines is increasingly re-
quired bymost journals in theﬁeld of life science. A description of cell cul-
tivation (including the reference of the producer and, if relevant, the size
of the plastic dishes), number of passages and whether the cells used in
experiments were collected from the exponential growth phase should
be presented. Furthermore, preparation of cells for treatment should in-
clude the composition of the buffer or medium, the state of the cells
(attached vs. suspension), trypsinization or scraping procedure and the
cell concentration. Concentration of the cells is highly important because
it might affect the sample conductivity during pulse application [23] and
theﬁeldhomogeneitywhen it is high [60,61]. Additionally, the availability
of drug to be introduced into cells can be reduced [29].
5.3. Plasmid DNA (pDNA) and other nucleic acid molecules
When using nucleic acids (including peptide nucleic acid), several pa-
rameters should be considered. For plasmids, a reference should be given
for the producer if commercially available plasmids are used or to the pat-
ent number if the plasmids are proprietary. Otherwise, a map of the plas-
mid should be supplied stating the size of the plasmid, the promoter used,
the therapeutic or reporter gene inserted and the selection marker. The
size of the plasmid is particularly important because in the case of smaller
plasmids, higher numbers of molecules are present in the suspension if
only the concentration (in mg/ml) is stated. Therefore, the molarity ofthe plasmid should also be included. The preparation procedure should
be clearly described, including a statement on endotoxin presence (test-
ing) and veriﬁcation of the plasmid size and purity. The vehicle in
which the plasmid is dissolved should be given. For siRNA, miRNA and
other small nucleic acids, including peptide-nucleic acids (PNA), the se-
quence should be supplied. All information listed for the plasmid DNA,
(concentration, molarity, vehicle data) should also be listed [62].
The use of control plasmids and other control nucleic acids is essen-
tial. The control plasmid should be devoid of the therapeutic gene and
ideally should have the same size as the therapeutic plasmid but with
a scrambled sequence. Speciﬁcally, nucleic acids represent foreign
DNA to cells (in vitro and in vivo) and can cause several different biolog-
ical cellular responseswith respect to its composition (e.g., the presence
of bacterial CpG sequences) [63–65]. This information is required to
supply a clear view of the possible biological responses.
6. Microscopy
Permeabilization and reporter gene expression procedures are rou-
tinely assayed using a ﬂuorescence approach, and ﬂuorescence micros-
copy reports a cellular description of the results. A precise description of
the microscope type (phase contrast, ﬂuorescence, confocal, biphoton)
is required together with a precise description of the different elements
(references of the objectives, light source, etc.) (Appendix 6). The size
and number of pixels of the camera should be given. The conditions of
the experiments should also be reported, as the integration time for
the camera, continuous or shuttered illumination. When possible, pic-
tures should be displayed using the same imaging protocols to allow di-
rect comparison. The procedure for image analysis and the software
used should also be included [66].
7. Animals in electroporation-based biomedical research
When animals are used in experiments [67], Directive 2010/63/EU
and/or U.S. Public Health Service Policy onHumane Care andUse of Lab-
oratory Animals guidelines should be followed. The experiments should
be conducted according to the following 3R principle: replacement, re-
duction and reﬁnement of the use of animals. The statement on ethical
approval of the study, including the approval number, should be
supplied.
A description of the animals (species, strain, sex, and age), the sup-
plier, and the animal housing conditions should be included. In addition,
if transgenic animals are used, their characteristics should be listed. The
number of animals included in each experimental group and the num-
ber of repetitions of the experiments should not be left out (http://
www.nih.gov/about/reporting-preclinical-research.htm). In addition,
Fig. 3. Schematic representation of growth curves. A growth curves of control and treated
tumors. The curves should be drawn to speciﬁc volumes (Vt) in all groups, and not only to
a speciﬁc time point (T) as in B, because the information onpossible tumor regrowth in the
treated group is therefore missing.
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and whether certain measurements or analyses were applied in a blind
fashion (e.g., histological analysis or tumor measurements). If possible,
animals of both sexes should be used to avoid gender differences in re-
sponse (Appendix 7).
7.1. Injection of substances and application of electric pulses in animal
experiments
As previously described for in vitro experiments, information on
substances injected into laboratory animals should follow speciﬁc
guidelines. The producer of the chemical, drug, plasmidDNA, etc. should
be stated. In cases in which the general name of the product is not
sufﬁciently speciﬁc (e.g., lipopolysaccharide or LPS), the catalog number
should also be supplied. Information on the route of administration and
speed of injection is important. Depending on the route of administra-
tion, the dose (in mg/kg for intravenous and intraperitoneal injec-
tion) or the concentration (in mg/ml for intra-tissue injection,
i.e., intramuscular, intratumoral, intradermal, subcutaneous, etc.)
should be stated. The injection volume and speed of injection [68],
including the size of the needle, should follow the guidelines for
the speciﬁc route of administration and speciﬁc animal species.
When combining the administration of substances with application
of electric pulses, the time interval between these two applications
should be speciﬁed. The term “immediately” should be avoided because
it is prone to different interpretations. Note also that delivery of electric
pulses affects blood perfusion [69] and can result in different efﬁcacies
of injected substances [70].
Associated with the description of the electrodes, it should also be
reported whether the electrodes are invasive or noninvasive. Further-
more, if shaving or depilation is required, the method should be de-
scribed. For tissue electroporation, is also essential that a detailed
description of the electrode placement is included. For example, inmus-
cle gene electrotransfer, due to the shape of muscle cells, the position of
the electrodes can play a major role in the effectiveness of transfection.
When the electric ﬁeld is oriented perpendicular to muscle cells, the
transfection is higher because a larger area of the membrane of muscle
cells is exposed to the electric ﬁeld above threshold for effective trans-
fection [71]. In addition, if conductive gel is used during the treatment
to ensure contact between the tissue/skin and electrodes, this item
needs to be listed, and details and abundance of use should be de-
scribed. The producer/manufacturer of the gel and the product number
should be reported, including the electrical conductivity of the gel if
possible. If the conductivity is not supplied by themanufacturer, the au-
thors should report how the conductivity was measured/determined
[72,73].
7.2. Preparation of animals: anesthesia
Another important aspect is the use of anesthesia and analgesia,
which can greatly affect the results from measurement of biological ef-
fects. The method of anesthesia and analgesia should be selected ac-
cording to established procedure and should comply with relevant
legislation. A considerable amount of relevant literature in this ﬁeld is
available and should be consulted [74–77].
7.3. Reporting results of animal studies
Depending on the type of study, the data pertinent to the aim of the
study should be presented. However, certain general data related to the
animals should also be reported, such as data on adverse effects. These
data should include bodyweight change as a general index of toxicity
and whether speciﬁc damage to the tissue used in the experiment oc-
curred. Furthermore, the use of non-invasive imaging techniques such
as ultrasound imaging, luminescence and ﬂuorescence imaging, CT,MRI, etc. should be implemented whenever possible to comply with
the 3Rs (reﬁnement, reduction, replacement) [71,78].
If working with tumor models, the method for measurement and
calculation of the tumor volume should be speciﬁed. Growth curves,
which state the increase in volume or diameter over time, should be
followed to the speciﬁc target volume V rather than at equal time
(Fig. 3A, B). If all animals in the control and treated groups are sacriﬁced
at the same day, then the growth of tumors is followed only to speciﬁc
time point T. In this case, if the treatment results in regression of the
tumor, the data on possible regrowth of the tumors are lost (Fig. 3B).
8. Conclusion
Reporting on applications of electric pulse delivery for electroporation
of biological samples in the life sciences requires a description of many
factors stemming from the multidisciplinary aspect of electroporation
(electropermeabilization). As general guidance in reporting experimental
data, a checklist is supplied to aid and guide the authors of research pa-
pers in writing and eventually improving the reproducibility of reports.
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Recommendaons and requirements for reporng electric pulse delivery for electroporaon of
biological samples
General remarks
The Guidelines for Authors for the journal should always be carefully observed.
...................................................................................................................................................................
Treatment informaon:
Study design, protocol details
Drug and chemical details (producer, dose, concentraon, route of administraon)
Electroporaon protocol, me interval between drug and chemical administraon and
electroporaon protocol (number of electric pulses applied)
Technical details of the electric pulse generator, including type, manufacturer and version of
soware, if applicable
Informaon on the pulsing chamber
Informaon on the electrodes (material, size and shape), according to tumor type
for the nanopulses: report on impedance adaptaon and connectors
Inclusion of a report on electrical parameters (n, T, U, I, f, polarity)*
* Legend: n = number; T = duraon of pulses; U = voltage amplitude applied; I = current measured; f = pulse repeon frequency
Culture condions
Reference to the cell type and its source.
□ Inial inoculum
□ Growth medium composion
□ Growth temperature
□ Incubaon me
□ Growth phase (exponenal or staonary)
Pulsing buﬀer
□ Conducvity and osmolarity of the medium
□ Temperature
Recovery condions
□ Time and storage condions between treatment and plang
□ Composion of the recovery medium
□ Incubaon me
□ Incubaon temperature
Reference to the animals used in experiments, strain, breeder, license
Type of anesthesia for preclinical studies
Tumor type, site of implantaon, number of tumor cells injected, volume of injecon, size of
the tumor at the beginning of treatment
..................................................................................................................................................................
Treatment outcome assessment:
Methods of response assessment (viability, biochemical responses)
Type of endpoint for assessment of eﬀecveness in vivo
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